Systematic review of cost and cost-effectiveness of different TB-screening strategies

详细信息    查看全文

• 作者：Albert Nienhaus (1)
  Anja Schablon (1)
  José Torres Costa (2)
  Roland Diel (3)
  
• 刊名：BMC Health Services Research
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：11
• 期：1
• 全文大小：211KB
• 参考文献：1. Jensen PA, Lambert LA, Lademarco MF, Ridzon R: Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. / MMWR Recomm Rep 2005, 54:1-41.
  2. Menzies D: What does tuberculin reactivity after bacille Calmette-Guerin vaccination tell us? / Clin Infect Dis 2000,31(Suppl 3):71-S74. CrossRef
  3. Andersen P, Munk ME, Pollock JM, Doherty TM: Specific immune-based diagnosis of tuberculosis. / Lancet 2000, 356:1099-104. CrossRef
  4. Nahid P, Pai M, Hopewell PC: Advances in the diagnosis and treatment of tuberculosis. / Proc Am Thorac Soc 2006, 3:103-10. CrossRef
  5. Pai M, Riley LW, Colford JM Jr: Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. / Lancet Infect Dis 2004, 4:761-76. CrossRef
  6. Menzies D, Pai M, Comstock G: Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. / Ann Intern Med 2007, 146:340-54.
  7. Diel R, Loddenkemper R, Nienhaus A: Evidence based comparison of commercial interferon-gamma release assays for detecting active tuberculosis - a meta-analysis. / Chest 2010, 137:952-68. CrossRef
  8. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A: Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. / Am J Respir Crit Care Med 2008, 177:1164-170. CrossRef
  9. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A: Negative and Positive Predictive Value of a Whole-Blood IGRA for Developing Active TB - An Update. / Am J Respir Crit Care Med 2010.
  10. Mazurek GH, Jereb J, Lobue P, Lademarco MF, Metchock B, Vernon A: Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. / MMWR Recomm Rep 2005, 54:49-5.
  11. National Institute for Health and Clinical Excellence: / Clinical Guidelines 33. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, UK; 2007.
  12. Diel R, For?bohm M, Loytved G, Haas W, Hauer B, Maffei D, / et al.: Recommendations for environmental contact tracing in tuberculosis. German Central Committee against Tuberculosis. / Gesundheitswesen 2007, 69:488-03. CrossRef
  13. Schweiz Lungenliga: Erkennung der Tuberkuloseinfektionen mittels Bluttest (Interfern-gamma). / BAG Bulletin 2005, 45:822-23.
  14. Mori T, Harada N: Cost-effectiveness analysis of QuantiFERON-TB 2nd generation used for detection of tuberculosis infection in contact investigations. / Kekkaku 2005, 80:675-86.
  15. Wrighton-Smith P, Zellweger JP: Direct costs of three models for the screening of latent tuberculosis infection. / Eur Respir J 2006, 28:45-0. CrossRef
  16. Fox BD, Kramer MR, Mor Z, Preiss R, Rusanov V, Fuks L, / et al.: The QuantiFERON-TB-GOLD assay for tuberculosis screening in healthcare workers: a cost-comparison analysis. / Lung 2009, 187:413-19. CrossRef
  17. Diel R, Nienhaus A, Lange C, Schaberg T: Cost optimisation of screening for latent tuberculosis in close contacts. / Eur Respir J 2006, 28:35-4. CrossRef
  18. Hardy AB, Varma R, Collyns T, Moffitt SJ, Mullarkey C, Watson JP: Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. / Thorax 2010, 65:178-80. CrossRef
  19. Diel R, Schaberg T, Loddenkemper R, Welte T, Nienhaus A: Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany. / Respir Med 2009, 103:1838-3. CrossRef
  20. Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, / et al.: German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. / Value Health 2008, 11:539-44. CrossRef
  21. Pooran A, Booth H, Miller RF, Scott G, Badri M, Huggett JF, / et al.: Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. / BMC Pulm Med 2010, 10:7. CrossRef
  22. Marra F, Marra CA, Sadatsafavi M, Moran-Mendoza O, Cook V, Elwood RK, / et al.: Cost-effectiveness of a new interferon-based blood assay, QuantiFERON(R)-TB Gold, in screening tuberculosis contacts. / Int J Tuberc Lung Dis 2008, 12:1414-424.
  23. Oxlade O, Schwartzman K, Menzies D: Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. / Int J Tuberc Lung Dis 2007, 11:16-6.
  24. Kowada A, Takahashi O, Shimbo T, Ohde S, Tokuda Y, Fukui T: Cost Effectiveness of Interferon-gamma Release Assay for Tuberculosis Contact Screening in Japan. / Mol Diagn Ther 2008, 12:235-51.
  25. de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH: Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. / Arch Intern Med 2009, 169:179-87. CrossRef
  26. Deuffic-Burban S, Atsou K, Viget N, Melliez H, Bouvet E, Yazdanpanah Y: Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection. / Int J Tuberc Lung Dis 2010, 14:471-81.
  27. Diel R, Nienhaus A, Loddenkemper R: Cost-effectiveness of Interferon-{gamma} Release Assay Screening for Latent Tuberculosis Infection Treatment in Germany. / Chest 2007, 131:1424-434. CrossRef
  28. Diel R, Wrighton-Smith P, Zellweger JP: Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis. / Eur Respir J 2007, 30:321-32. CrossRef
  29. Diel R, Loddenkemper R, Nienhaus A: Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. / Chest 2010, 137:952-68. CrossRef
  30. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, / et al.: Interferon-{gamma} release assays for the diagnosis of latent M. tuberculosis infection: A systematic review and meta-analysis. / Eur Respir J 2010, in press.
  31. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6963/11/247/prepub
  
• 作者单位：Albert Nienhaus (1)
  Anja Schablon (1)
  José Torres Costa (2)
  Roland Diel (3)
  
  1. Institute for Health Service Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  2. Occupational Health Division, S. Jo?o Hospital, EPE, Porto, Portugal
  3. Department of Pneumology, Medical School Hannover, Hannover, Germany
  

文摘

Background Interferon-γ release assays (IGRAs) for TB have the potential to replace the tuberculin skin test (TST) in screening for latent tuberculosis infection (LTBI). The higher per-test cost of IGRAs may be compensated for by lower post-screening costs (medical attention, chest x-rays and chemoprevention), given the higher specificity of the new tests as compared to that of the conventional TST. We conducted a systematic review of all publications that have addressed the cost or cost-effectiveness of IGRAs. The objective of this report was to undertake a structured review and critical appraisal of the methods used for the model-based cost-effectiveness analysis of TB screening programmes. Methods Using Medline and Embase, 75 publications that contained the terms "IGRA", "tuberculosis" and "cost" were identified. Of these, 13 were original studies on the costs or cost-effectiveness of IGRAs. Results The 13 relevant studies come from five low-to-medium TB-incidence countries. Five studies took only the costs of screening into consideration, while eight studies analysed the cost-effectiveness of different screening strategies. Screening was performed in high-risk groups: close contacts, immigrants from high-incidence countries and healthcare workers. Two studies used the T-SPOT.TB as an IGRA and the other studies used the QuantiFERON-TB Gold and/or Gold In-Tube test. All 13 studies observed a decrease in costs when the IGRAs were used. Six studies compared the use of an IGRA as a test to confirm a positive TST (TST/IGRA strategy) to the use of an IGRA-only strategy. In four of these studies, the two-step strategy and in two the IGRA-only strategy was more cost-effective. Assumptions about TST specificity and progression risk after a positive test had the greatest influence on determining which IGRA strategy was more cost-effective. Conclusion The available studies on cost-effectiveness provide strong evidence in support of the use of IGRAs in screening risk groups such as HCWs, immigrants from high-incidence countries and close contacts. So far, only two studies provide evidence that the IGRA-only screening strategy is more cost-effective.